| Sleepless Nights for Somaxon: Will It Find a Partner for Its Insomnia Drug? Richard Sater submits:On March 18, 2010, Somaxon Pharmaxeuticals (SOMX) was granted FDA approval to sell Silenor 3 and 6 mg. tablets for the treatment of insomnia characterized by difficulty with sleep maintenance. This approval was met with a stock price move from 4 to 10 dollars. Shares were only 30 cents just one year earlier. The stock has lost half its value since the day after FDA approval to just above 5 dollars. Can the stock rebound or will the price continue to drop? Silenor is a unique dose of the compound doxepin (Sinequan) which is available as a generic in 10, 25, 50, 75, 100 and 150 mg capsules and a 10 mg/ml concentrate liquid. Silenor’s mechanism of action is likely due to histamine blocking. This is a different mechanism from Ambien (Sanofi-Aventis (SNY)), Lunesta (Sepracor (SEPR)) and Sonata (King Pharmaceuticals (KG)) which work through the GABAalpha1 receptor or from Rozerem (Takeda Pharmaceuticals (TKPHF.PK)) that works through the melatonin receptor.Complete Story » seekingalpha.com |
Clarient to Present at Two Investor Conferences in August (PR Newswire) Clarient, Inc. , a premier anatomic pathology and molecular testing services resource for pathologists, oncologists and the biopharmaceutical industry, today announced that the Company is scheduled to make investor presentations at two investor conferences in the month of August. us.rd.yahoo.com |
Abbott Eyes India for Shot in Arm India's market leader in medicines will soon be based near Lake Michigan. Abbott will hold the biggest share of India's pharmaceuticals market when the company closes its $3.7 billion takeover of the drugs business of Piramal Healthcare. online.wsj.com |
Abbott Profit Falls 40% on Acquisition, Recall Costs Abbott reported a 40% drop in third-quarter earnings, weighed down by costs associated with layoffs, a baby-formula recall and the withdrawal of a diet drug due to safety concerns. online.wsj.com |
Top 10 Global Biopharmaceutical Companies David Hunkar submits: A few days ago we reviewed the top 20 global pharmaceutical companies by sales. In this post, lets take a quick look at the top 10 global biopharmaceutical firms based on 2009 revenues. The table below lists the Top 10 Global Biopharmaceutical Companies by Sales. These firms were selected based on the following rule:Complete Story » seekingalpha.com |